Nantahala Capital Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,744,124
| Closed | -$58.4M | – | 173 |
|
|
2026
Q1 | $58.4M | Buy |
1,744,124
+430,122
| +33% | +$16.9M | 2.15% | 8 |
|
|
2025
Q4 | $60.8M | Buy |
1,314,002
+450,239
| +52% | +$24.7M | 2.01% | 9 |
|
|
2025
Q3 | $58.4M | Sell |
863,763
-137,587
| -14% | -$10.2M | 2.03% | 8 |
|
|
2025
Q2 | $83.9M | Sell |
1,001,350
-755,673
| -43% | -$56.6M | 3.29% | 2 |
|
|
2025
Q1 | $126M | Sell |
1,757,023
-2,171,943
| -55% | -$106M | 4.99% | 4 |
|
|
2024
Q4 | $177M | Buy |
3,928,966
+658,518
| +20% | +$34.1M | 7.58% | 2 |
|
|
2024
Q3 | $165M | Buy |
3,270,448
+188,341
| +6% | +$9.02M | 8.35% | 2 |
|
|
2024
Q2 | $126M | Buy |
3,082,107
+671,728
| +28% | +$28.5M | 7.35% | 3 |
|
|
2024
Q1 | $103M | Sell |
2,410,379
-445,972
| -16% | -$20.2M | 5.89% | 3 |
|
|
2023
Q4 | $115M | Buy |
2,856,351
+2,463,947
| +628% | +$70.1M | 6.87% | 3 |
|
|
2023
Q3 | $11.6M | Sell |
392,404
-257,437
| -40% | -$1.56M | 0.99% | 20 |
|
|
2023
Q2 | $2.79M | Sell |
649,841
-49,523
| -7% | -$213K | 0.27% | 71 |
|
|
2023
Q1 | $1.5M | Buy |
699,364
+95,185
| +16% | +$214K | 0.11% | 81 |
|
|
2022
Q4 | $1.2M | Hold |
604,179
| – | – | 0.08% | 84 |
|
|
2022
Q3 | $1.01M | Sell |
604,179
-24,922
| -4% | -$60.7K | 0.07% | 88 |
|
|
2022
Q2 | $1.68M | Hold |
629,101
| – | – | 0.08% | 86 |
|
|
2022
Q1 | $2.1M | Sell |
629,101
-21,908
| -3% | -$113K | 0.09% | 86 |
|
|
2021
Q4 | $4M | Hold |
651,009
| – | – | 0.14% | 82 |
|
|
2021
Q3 | $9.03M | Hold |
651,009
| – | – | 0.28% | 69 |
|
|
2021
Q2 | $11.1M | Buy |
651,009
+129,894
| +25% | +$2.19M | 0.32% | 66 |
|
|
2021
Q1 | $9.85M | Sell |
521,115
-3,642
| -0.7% | -$117K | 0.29% | 66 |
|
|
2020
Q4 | $15.2M | Buy |
524,757
+29,666
| +6% | +$856K | 0.47% | 51 |
|
|
2020
Q3 | $18.6M | Hold |
495,091
| – | – | 0.57% | 40 |
|
|
2020
Q2 | $16.5M | Buy |
495,091
+209,896
| +74% | +$9.1M | 0.5% | 45 |
|
|
2020
Q1 | $10.2M | Hold |
285,195
| – | – | 0.38% | 44 |
|
|
2019
Q4 | $12.6M | Buy |
+285,195
| New | +$7.3M | 0.39% | 46 |
|
Nantahala Capital Management's SLNO Position: Q2 2026 in Review
Nantahala Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,744,124 shares — an estimated $58.4M sold.
Nantahala Capital Management first reported a position in SLNO in Q4 2019 and held it in 26 quarters. The position peaked at $177M in Q4 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Nantahala Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Nantahala Capital Management sold 1,744,124 Soleno Therapeutics shares in Q2 2026, an estimated $58.4M.
- Nantahala Capital Management first reported a position in Soleno Therapeutics in Q4 2019 and held it in 26 quarters.
- Nantahala Capital Management's Soleno Therapeutics position peaked at $177M in Q4 2024.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.